
    
      To evaluate the potential of DSXS to suppress HPA axis function in patients with mild to
      moderate plaque psoriasis.

      To evaluate the efficacy parameters and adverse event (AE) profile of DSXS administered to
      patients with mild to moderate plaque psoriasis.
    
  